Monoclonal Antibody (mABs) Therapeutics Market

The report "Monoclonal Antibody (mABs) Therapeutics Market by Production Method (In-Vitro, In-Vivo), Sources (Human, Chimeric), Route of Administration (Intravenous, Subcutaneous), Therapy (Inflammatory & Autoimmune, Oncology, Hematology) - Global Forecast to 2029", is projected to reach USD 497.5 billion by 2029 from an estimated USD 252.6 billion in 2024, at a CAGR of 14.5% during the forecast period of 2024-2029.

Browse 365 market data Tables and 58 Figures spread through 350 Pages and in-depth TOC on "Monoclonal Antibody (mABs) Therapeutics Market by Production Method (In-Vitro, In-Vivo), Sources (Human, Chimeric), Route of Administration (Intravenous, Subcutaneous), Therapy (Inflammatory & Autoimmune, Oncology, Hematology) - Global Forecast to 2029"
View detailed Table of Content here - https://www.marketsandmarkets.com/Market-Reports/monoclonal-antibody-mabs-therapeutics-market-115323820.html

The monoclonal antibody therapeutics market is primarily driven by factors such as increasing prevalence of chronic diseases like cancer, autoimmune disorders, and infectious diseases. Technological advancements in antibody engineering and production processes also contribute significantly. Additionally, growing investments in research and development, coupled with expanding applications in personalized medicine, drive market growth. For example, drugs like rituximab (used for lymphoma and leukemia) and trastuzumab (used for breast cancer) exemplify the success and potential of monoclonal antibody therapeutics.

The In-Vitro accounted for the largest share of production method in the monoclonal antibody therapeutics market in 2023.

By Production Method, the monoclonal antibody therapeutics market is segmented into in-vitro and in-vivo. In-Vitro for the largest share of the monoclonal antibody therapeutics market in 2023. The in vitro production method for monoclonal antibody therapeutics is propelled by factors such as scalability, cost-effectiveness, and reduced risk of contamination compared to traditional in vivo methods. Advancements in cell culture technologies and bioprocessing techniques have enhanced productivity and consistency. Moreover, regulatory agencies favor in vitro production for its quality control advantages.

The human source segment is expected to grow at a higher rate during the forecast period.

Based on sources, monoclonal antibody therapeutics market is segmented into human, humanized, chimeric and other sources. In 2023, human segment accounted for the largest share of the monoclonal antibody therapeutics market and humanized segment is expected to grow at a higher growth rate during the forecast period of 2024-2029. The human source monoclonal antibody therapeutics market is propelled by factors such as reduced immunogenicity, improved efficacy, and enhanced safety profiles compared to non-human sources. Increasing demand for precision medicine and personalized therapies also drives market growth. Technological advancements in antibody discovery platforms, such as phage display and transgenic mice, further accelerate development timelines. Examples include adalimumab (Humira) for autoimmune diseases and pembrolizumab (Keytruda) for cancer, highlighting the success and potential of human-sourced monoclonal antibody therapeutics in addressing diverse medical needs.

The autoimmune and inflammatory segment accounted for the largest share of the therapy area segment in the monoclonal antibody therapeutics market in 2023.

Based on therapy area the monoclonal antibody therapeutics market is segmented into autoimmune & inflammatory disorders, oncology, hematology, opthalmology and other therapy area. In 2023, autoimmune & inflammatory diseases segment dominated the monoclonal antibody therapeutics market. The monoclonal antibody therapeutics market for autoimmune and inflammatory diseases and cancer is driven by several factors. For autoimmune and inflammatory diseases, increasing prevalence, unmet medical needs, and advancements in targeted therapies propel market growth. Examples include adalimumab (Humira) for rheumatoid arthritis and infliximab (Remicade) for Crohn's disease. In cancer, rising incidence rates, expanding treatment options, and personalized medicine approaches contribute to market expansion.

The hospitals accounted for the largest share of end user in the monoclonal antibody therapeutics market in 2023.

By end user, hospitals, long-term care facilities, and other end users. In 2023, hospitals accounted for the largest share of the monoclonal antibody therapeutics market. The monoclonal antibody therapeutics market for hospitals is driven by factors such as increasing patient admissions, advancements in healthcare infrastructure, and growing demand for advanced treatments. Examples include hospitals incorporating monoclonal antibody therapies like bevacizumab (Avastin) for cancer into their treatment regimens, enhancing patient care and outcomes

Europe is likely to grow at significant CAGR during forecast period of 2024-2029.

The monoclonal antibody therapeutics market is segmented into North America, Europe, Asia Pacific (APAC), Latin America (LATAM), the Middle East, and Africa. North America dominated the monoclonal antibody therapeutics market. Europe's accelerated growth is attributed to several factors. Robust healthcare infrastructure, favorable government policies, increased research and development investments, rising prevalence of chronic diseases, and expanding adoption of innovative medical technologies. Additionally, collaborations between academia, industry, and regulatory bodies further drive advancements in healthcare, propelling Europe towards faster-paced growth in various medical sectors.

Key players in the monoclonal antibody therapeutics market are F. Hoffmann-La Roche Ltd (Switzerland), Abbvie Inc. (US), Johnson & Johnson Services, Inc. (US), Merck & Co., Inc. (US), Bristol Myers Squibb Company (US), AstraZeneca (UK), Sanofi (France), Novartis AG (Switzerland), Amgen Inc. (US), Takeda Pharmaceutical Company Limited (Japan), GSK plc. (UK), Eli Lilly and Company (US), Regeneron Pharmaceuticals Inc. (US), and among others.

Don’t miss out on business opportunities in Monoclonal Antibody (mABs) Therapeutics Market. Speak to our analyst and gain crucial industry insights that will help your business grow.

About MarketsandMarkets™

MarketsandMarkets™ provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies’ revenues. Currently servicing 7500 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach MarketsandMarkets™ for their painpoints around revenues decisions.

Our 850 fulltime analyst and SMEs at MarketsandMarkets™ are tracking global high growth markets following the "Growth Engagement Model – GEM". The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write "Attack, avoid and defend" strategies, identify sources of incremental revenues for both the company and its competitors. MarketsandMarkets™ now coming up with 1,500 MicroQuadrants (Positioning top players across leaders, emerging companies, innovators, strategic players) annually in high growth emerging segments. MarketsandMarkets™ is determined to benefit more than 10,000 companies this year for their revenue planning and help them take their innovations/disruptions early to the market by providing them research ahead of the curve.

MarketsandMarkets’s flagship competitive intelligence and market research platform, "Knowledgestore" connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets.

Contact:
Mr. Aashish Mehra
MarketsandMarkets™ INC.
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA : 1-888-600-6441
[email protected]